1. Home
  2. IOVA vs SIGIP Comparison

IOVA vs SIGIP Comparison

Compare IOVA & SIGIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.80

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

SIGIP

Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

HOLD

Current Price

$16.46

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
SIGIP
Founded
2007
N/A
Country
United States
United States
Employees
N/A
2800
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
N/A
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
IOVA
SIGIP
Price
$3.80
$16.46
Analyst Decision
Buy
Analyst Count
10
0
Target Price
$9.11
N/A
AVG Volume (30 Days)
17.8M
4.2K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
14.84
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$49.14
N/A
Revenue Next Year
$51.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.64
$16.41
52 Week High
$5.63
$18.71

Technical Indicators

Market Signals
Indicator
IOVA
SIGIP
Relative Strength Index (RSI) 50.48 29.41
Support Level $1.99 N/A
Resistance Level $4.34 $17.07
Average True Range (ATR) 0.44 0.13
MACD -0.13 -0.04
Stochastic Oscillator 11.65 0.00

Price Performance

Historical Comparison
IOVA
SIGIP

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About SIGIP Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. Majority of revenue is gained from Standard Commercial Lines segment, which comprises of property and casualty insurance products and services provided in the standard marketplace to commercial enterprises, which are typically businesses, non-profit organizations, and local government agencies.

Share on Social Networks: